Recent News from NIH and FDA
NIH-sponsored researchers announced the following news at the Conference on Retroviruses and Opportunistic Infections (CROI) this week:
March 4, 2013: Daily-Use HIV Prevention Approaches Prove Ineffective Among Women in NIH Study
“Three antiretroviral-based strategies intended to prevent HIV infection among women did not prove effective in a major clinical trial in Africa.”
Read the NIH press release.
March 3, 2013: Toddler ‘Functionally Cured’ of HIV Infection, NIH-Supported Investigators Report
“A two-year-old child born with HIV infection and treated with antiretroviral drugs beginning in the first days of life no longer has detectable levels of virus using conventional testing despite not taking HIV medication for 10 months … .”
Read the NIAID press release.
FDA recently announced the following labeling updates:
March 1, 2013: Intelence (Etravirine) Labeling Updates
“FDA approved changes to the Intelence (etravirine) label to include revisions to the Warnings and Precautions, Adverse Reactions, and Postmarketing Experience sections … .”
Read the FDA announcement and view the AIDSinfo patient drug summary for etravirine.
March 1, 2013: Prezista (Darunavir) Label Change - Drug Interaction Information
“The FDA recently approved changes to the Prezista (darunavir) label to reflect drug int...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - Category: Infectious Diseases Source Type: news
More News: African Health | Children | Clinical Trials | Conferences | Department of Health | Health | HIV AIDS | Infectious Diseases | Prezista | Study | Warnings | Women